Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by rtftech16on Feb 20, 2018 1:51pm

103 Views

Post# 27588667

RE:RE:0.29 is holding so far

All I'm saying is as of today there are way less buyers in the 0.30-0.32 range than there are sellers, which would indicate very few people are willing to pay more than 0.30 pre news. There are way more buyers at a price of less than 0.295, which would indicate people are comfortable buying when the price is less than 0.295 pre news. Unless this trend is broken it shall remain until negative news or positive news is released.

Bullboard Posts

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles